She expected her body to change when she started taking Zepbound. But nobody told her what might happen to her marriage.
Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli ...
The U.S. Centers for Medicare and Medicaid Services on Tuesday unveiled a voluntary program to cover GLP-1 drugs for weight-loss and diabetes under Medicaid and Medicare Part D plans, following the ...
Novo Nordisk's pill could be a convenient new option for adults seeking to lose weight. The worldwide market for weight-loss drugs could grow to a staggering $150 billion in the coming decade. The ...
Asianet Newsable on MSN
Top 5 US healthcare stocks by market value
Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback